Search Results
Jul 01, 2026, 10:31 ET High-Grade Glioma Market Witnesses Strong Momentum During the Forecast Period (2026-2036) with Increasing Clinical Activity and Drug Development | DelveInsight
(pemigatinib), Paxalisib (GDC-0084), BMX-001, Bizaxofusp (MDNA55), ITI-1000 (PP65 DC vaccine), SURVAXM, OKN-007, BERUBICIN, GLIOVAC/SITOIGANAP, IGV-001, BGB-290, EO2401, VBI-1901, TEMFERON, NOX-A12 (OLAPTESED PEGOL), INO-5401+ INO-9012+ LIBTAYO (cemiplimab), Lerapolturev, Rhenium (186RE) obisbemeda, and
More news about: DelveInsight Business Research, LLP
May 26, 2026, 12:53 ET John Theurer Cancer Center at Hackensack University Medical Center Presents Innovative Cancer Research at Major Annual Cancer Meeting
A phase 1 study of BGB-A3055 (anti-CCR8) with or without tislelizumab (anti–PD-1) in patients with solid tumors.Melanoma
More news about: Hackensack Meridian John Theurer Cancer Center
Jan 06, 2026, 20:30 ET 亞盛醫藥BTK降解劑APG-3288的新藥臨床申請（IND）獲美國FDA許可
Y., et al., Translational modelling to predict human pharmacokinetics and pharmacodynamics of a Bruton's tyrosine kinase‐targeted protein degrader BGB‐16673. British Journal of Pharmacology, 2024. 181(24): p. 4973-4987.關於亞盛醫藥亞盛醫藥是一家綜合性的全球生物醫藥企業，致力於研發
More news about: 亞盛醫藥
Jan 06, 2026, 03:19 ET Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
BGB-16673 developed by BeOne Medicines | Chronic lymphocytic leukemia/small lymphocytic lymphomaA BTK-targeting chimeric degradation activation
More news about: Clarivate Plc
Jan 06, 2026, 03:07 ET Clarivate Identifies Eleven Potential Blockbuster and Transformative Therapies in its 2026 Drugs to Watch Report
BGB-16673 developed by BeOne Medicines | Chronic lymphocytic leukemia/small lymphocytic lymphomaA BTK-targeting chimeric degradation activation
More news about: Clarivate Plc
Nov 21, 2025, 12:39 ET Hackensack Meridian John Theurer Cancer Center Unveils Research at the 67th American Society of Hematology Annual Meeting
results from KOMET-007 (ABSTRACT 25-3910) MRD-guided therapy of sonrotoclax (BGB-11417) + obinutuzumab (O) in patients with treatment-naive CLL: Initial results from an ongoing phase 1/1b study, BGB-11417-101 (ABSTRACT 25-7489) Real world outcomes of bispecific T-cell engagers
More news about: Hackensack Meridian John Theurer Cancer Center
Nov 05, 2025, 03:00 ET Bitget Becomes the First UEX to Integrate Morph Chain, Advancing Its Onchain Ecosystem
Bitget transferred 440M BGB to Morph, integrating BGB as its native token. Together, the two platforms are laying the foundation for fast, borderless, and programmable payments
More news about: Bitget
Nov 05, 2025, 03:00 ET Bitget Becomes the First UEX to Integrate Morph Chain, Advancing Its Onchain Ecosystem
Bitget transferred 440M BGB to Morph, integrating BGB as its native token. Together, the two platforms are laying the foundation for fast, borderless, and programmable payments powered by
More news about: Bitget
Oct 31, 2025, 11:18 ET Bitget GetAgent Lets You "Ask Satoshi" 17 Years Later
Bitget's premium AI tier. Following the trial period, 50 participants will be selected to receive a one-month GetAgent Ultra Membership, each valued at 25 BGB. Additionally, during the Bitcoin Whitepaper Day 24H Blitz from October 31 at 18:00 to November 1 at 18:00 (UTC+8), 1,000 users who ask Satoshi-related
More news about: Bitget
Oct 31, 2025, 11:08 ET Bitget GetAgent Lets You "Ask Satoshi" 17 Years Later
Bitget's premium AI tier. Following the trial period, 50 participants will be selected to receive a one-month GetAgent Ultra Membership, each valued at 25 BGB. Additionally, during the Bitcoin Whitepaper Day 24H Blitz from October 31 at 18:00 to November 1 at 18:00 (UTC+8), 1,000 users who
More news about: Bitget
Oct 29, 2025, 08:00 ET InSysBio to announce its collaboration with BeOne Medicines
support the selection of the optimal recommended phase 2 dose by predicting the dynamics of the various complexes formed when the BGB-B2033 binds to its targets. BGB-B2033, a GPC3 x 4-1BB bispecific antibody, is currently in early clinical development by BeOne Medicines. "This project
More news about: InSysBio
Oct 16, 2025, 17:31 ET Indolent Lymphoma Market Experiences Significant Growth Amid Evolving Therapeutic Landscape | DelveInsight
lymphoma market in the coming years. The promising indolent lymphoma therapies in clinical trials include AZD0486, BGB-16673, Sonrotoclax + Zanubrutinib, Abexinostat, EO2463, NVG-111, ZE50-0134, and others. Discover the indolent
More news about: DelveInsight Business Research, LLP
Oct 15, 2025, 00:01 ET Brands adapting to market challenges increases the total value of Interbrand's 2025 Best Global Brands by $150 billion
Electric (#65), Monster (#70), Nasdaq (#85), BYD (#90) and Shopify (#99) have joined the rankings marking the highest number of new entrants for any BGB report. Media businesses surge Digital media and entertainment
More news about: Interbrand